Beractant


Thông tin thuốc gốc
Chỉ định và Liều dùng
Endotracheal
Neonatal respiratory distress syndrome
Child: Dose is expressed in terms of phospholipids; each mL contains beractant equivalent to 25 mg phospholipids (4 mL contains 100 mg phospholipids). As treatment in premature neonates: Initially, 100 mg phospholipids/kg (4 mL/kg) given as soon as possible after the diagnosis of RDS is confirmed by radiographic or clinical findings, preferably within 8 hours of birth. If necessary, the dose may be repeated at intervals of at least 6 hours for up to a Max of 4 doses within the 1st 48 hours of life. As prophylaxis in premature neonates at risk of developing RDS with evidence of surfactant deficiency: Initially, 100 mg phospholipids/kg (4 mL/kg) given as soon as possible after birth, preferably within 15 minutes. If necessary, the dose may be repeated at intervals of at least 6 hours for up to a Max of 4 doses within the 1st 48 hours of life. Doses are administered via an endotracheal tube. Specific methods of administration may vary depending on the ventilation technique. Refer to detailed product guidelines for instructions on administration.
Thận trọng
Marked improvements in lung oxygenation and compliance may occur within minutes of administration; frequent and appropriate adjustments to oxygen delivery and ventilator settings may be required to avoid hyperoxia. Premature neonates. Use of beractant in neonates <600 g or >1,750 g birth weight has not been evaluated in controlled clinical trials.
Tác dụng không mong muốn
Significant: Transient bradycardia and oxygen desaturation; increased risk of nosocomial sepsis (post-treatment); transient rales and moist breath sounds; endotracheal tube obstruction by mucous secretions.
General disorders and administration site conditions: Rarely, pallor.
Nervous system disorders: Intracranial haemorrhage.
Respiratory, thoracic and mediastinal disorders: Pulmonary haemorrhage. Rarely, hypocapnia, hypercapnia, apnoea, endotracheal tube reflux.
Vascular disorders: Rarely, hypertension, hypotension, vasoconstriction.
Chỉ số theo dõi
Closely monitor continuous ECG and arterial or transcutaneous systemic oxygen and CO2 measurements during administration; arterial blood gases after administration.
Tác dụng
Description: Beractant, an exogenous pulmonary surfactant, is a modified bovine lung extract containing mainly phospholipids. It replaces deficient or ineffective endogenous lung surfactant in neonates with or at risk of developing respiratory distress syndrome (RDS). Beractant acts by reducing the surface tension between air and alveolar surfaces, thereby stabilising the alveoli against collapse during respiration and increasing alveolar ventilation.
Onset: Improved oxygenation: Within minutes.
Pharmacokinetics:
Distribution: Rapidly distributes to the alveolar surfaces.
Bảo quản
Store between 2-8°C. Do not freeze. Protect from light. Do not shake. Recommendations on the stability and storage of unopened vials once warmed may vary between countries. Refer to detailed product guidelines.
Phân loại MIMS
Các thuốc khác có tác dụng trên hệ hô hấp
Tài liệu tham khảo
Anon. Beractant. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 07/03/2022.

Anon. Beractant. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/03/2022.

Buckingham R (ed). Pulmonary Surfactants. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/03/2022.

Survanta 25 mg/mL Suspension (AbbVie Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 07/03/2022.

Survanta Suspension (AbbVie Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 07/03/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Beractant từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in